Potency, selectivity and prolonged binding of saxagliptin to DPP4: Maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor

BMC Pharmacology

Volumn 12, Issue , 2012, Pages

  Wang, Aiying ^a   Dorso, Charles ^a   Kopcho, Lisa ^b   Locke, Gregory ^b   Langish, Robert ^c   Harstad, Eric ^d   Shipkova, Petia ^c   Marcinkeviciene, Jovita ^b   Hamann, Lawrence ^e   Kirby, Mark S ^a  

^a Departments of Metabolic Diseases Diabetes   (United States)

^b Chemical Enzymology   (United States)

^c Bioanalytical and Discovery Analytical Sciences   (United States)

^d Drug Safety Evaluation and   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYSAXAGLIPTIN; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; SAXAGLIPTIN; SITAGLIPTIN; UNCLASSIFIED DRUG; VILDAGLIPTIN; 5-HYDROXYSAXAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDASE; DIPEPTIDE; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DPP8 PROTEIN, HUMAN; DPP9 PROTEIN, HUMAN; DRUG DERIVATIVE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; NITRILE; PYRAZINE DERIVATIVE; PYRROLIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; ASSAY; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; HORMONE RELEASE; HUMAN; IN VITRO STUDY; NONHUMAN; ALGORITHM; ANIMAL; ARTIFACT; BLOOD; COMPARATIVE STUDY; KINETICS; MACACA FASCICULARIS; METABOLISM; MOLECULAR CLONING; PROTEIN BINDING; SPECIES DIFFERENCE;

ADAMANTANE; ALGORITHMS; ANIMALS; ARTIFACTS; CLONING, MOLECULAR; DIPEPTIDASES; DIPEPTIDES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INDICATORS AND REAGENTS; KINETICS; MACACA FASCICULARIS; NITRILES; PROTEIN BINDING; PYRAZINES; PYRROLIDINES; SPECIES SPECIFICITY; TRIAZOLES;

EID: 84859172957     PISSN: None     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-12-2     Document Type: Article

References (28)

1. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58:773-795.
2. Holst JJ. Enteroglucagon Ann Rev Physiol 1997, 59:257-271.
3. Nauck MA, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin dependent) diabetes. Diabetologia 1986, 29:46-52.
4. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91:301-307.
5. Vilsboll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endo Metab 2003, 88:220-224.
6. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010, 30:463-484.
7. Deacon CF, Holst JJ. Saxagliptin: a new dipeptidylpeptidase-4 inhibitor for the treatment of type 2 diabetes. Adv Ther 2009, 26:488-499.
8. Zerilli T, Pyon EY. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clin Ther 2007, 29:2614-2634.
9. Mu J, Petrov A, Eiermann GJ, Woods J, Zhou Y-P, Li Z, Zycband W, Feng Y, Zhu L, Roy RS, Howard AD, Li C, Thornberry NA, Zhang BB. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharmacol 2009, 623:148-154.
10. Copeland RA, Harpel MR, Tummino PJ. Targeting enzyme inhibitors in drug discovery. Expert Opin Ther Targets 2007, 11:967-978.
11. Morrison JF, Walsh CT. The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol 1988, 61:201-301.
12. Hughes TE, Mone MD, Russell ME, Weldon SC, Villhauer EB. NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry 1999, 38:11597-11603.
13. Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, Wang A, Simpkins LM, Taunk P, Huang Q, et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005, 48:5025-5037.
14. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors. J Pharm Exp Thera 2008, 325:175-182.
15. Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Disc 2006, 5:730-739.
16. De Leon DD, Crutchlow MF, Ham J-YN, Stoffers DA. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int J Biochem Cell Biol 2006, 38:845-849.
17. Kirby M, Yu DMT, O' Connor SP, Gorrell MD. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci 2010, 118:31-41.
18. Fura A, Khanna A, Vyas V, Koplowitz B, Chang S-Y, Caporuscio C, Boulton DW, Christopher LW, Chadwick KD, Hamann LG, Humphreys WG, Kirby M. Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections. Drug Metab Disp 2009, 37:1164-1171.
19. Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drug 2010, 19:133-140.
20. Kim YB, Kopcho LM, Kirby MS, Hamann LG, Weigelt CA, Metzler WJ, Marcinkeviciene J. Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118). Arch Biochem Biophys 2006, 445:9-18.
21. Ajami K, Pitman MR, Wilson CH, Park J, Menz RI, Starr AE, Cox JH, Abbott CA, Overall CM, Gorrell MD. Stromal cell-derived factors 1a and 1b, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8. FEBS Letters 2008, 582:819-825.
22. Krishna R, Herman G, Wagner JA. Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes. AAPS J 2008, 10:401-409.
23. Boulton DW, Geraldes M. Safety, tolerability, pharmacokinetics and pharmacodynamics of once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetics and healthy subjects. Diabetes 2007, 56:A161.
24. Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a didpeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006, 28:55-72.
25. He YL, Sabo R, Campestrini J, Wang Y, Riviere GJ, Nielsen JC, Rosenberg M, Ligueros-Saylan M, Howard D, Dole WP. The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers. Br J Clin Pharmacol 2008, 65:338-46.
26. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005, 48:612-615.
27. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE. 1-[[(3-hydroxy-1-adamantyl)amino] acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003, 46:2774-2789.
28. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8 H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005, 48:141-151.